TP53 and hepatocellular carcinoma: HCC is a highly heterogeneous malignancy with a complex pathophysiology.1,2 Integrative genomic analyses have defined the landscape of genetic alterations in HCC, enabling the classification of the disease into two molecular subtypes.1,3 The proliferation class, which is characterized by activation of oncogenic signaling pathways, TP53 mutations, and expression of progenitor cell markers, is associated with a more aggressive phenotype.